| Ytd | -20.50% | |
| 1y | -74.76% |
| Open | 3.42 | Prev Close | 3.40 | Low | 3.16 | High | 3.37 | Mkt Cap | 6.81M |
| Vol | 48.10K | Avg Vol | 1.41M | EPS | -10.75 | P/E | N/A | Forward P/E | -2.00 |
| Beta | 0.57 | Short Ratio | 1.96 | Inst. Own | 8.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-01 | 50-d Avg | 3.31 | 200-d Avg | 4.00 | 1yr Est | 14.00 |
CANF News
The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Ph
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Ph
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Na
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory intera
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory intera
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced d
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (
Interim analysis to be conducted under an FDA- and EMA-agreed protocolRamat Gan, Israel, July 06, 20
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF)
Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular se
Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced
Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, suppo
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDA
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced d
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic di
Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m
ON: -14% | ON stock has given up its prior gain. ON Semiconductor shares were trading higher after t
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets a
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and f
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr
Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (
Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease R
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing
Growing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and enco
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr
Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (T
D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy a
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advan
Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advan
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) w
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing
Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)
Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs ass
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, Ma
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeuti
U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a bi
Can-Fite stock jumps after Namodenoson improves survival in pancreatic cancer Phase 2a study with a